A Phase 3 interventional study of Rosuvastatin 20mg in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by AstraZeneca. Completed at 6 sites in 6 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-02-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.
This is a long-term extension (LTE) to the randomized, double-blind, cross-over study of rosuvastatin 20 mg once daily (QD) versus placebo QD in children and adolescents (aged from 6 to \<18 years) with homozygous familial hypercholesterolemia (HoFH) (Study D3561C00004).
The study is designed to assess the long-term safety and tolerability of rosuvastatin 20 mg in pediatric patients with HoFH.
In this study all patients will receive rosuvastatin 20 mg QD. Investigators will also be permitted to titrate the dose of rosuvastatin from 20 to 40 mg per day if they feel it is warranted to more aggressively treat patients' elevated LDL-C levels. This up-titration will not be permitted in Asian patients. Pharmacokinetic data of the trough plasma exposure of rosuvastatin will also be assessed for the pediatric patients with HoFH taking a daily dose of rosuvastatin 40 mg.
The primary outcome measures to be assessed include 1) Adverse events, including:
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 9 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female children and adolescents who were aged 6 to \<18 years at the onset of Study D3561C00004 (even if they had their 18th birthday during that study) with:
Documented untreated LDL C >500 mg/dL (12.9 mmol/L) and TG \<400 mg/dL (4.5 mmol/L) and at least 1 of the following criteria:
Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in females of child bearing potential:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One treatment period for all patients (\<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
Drug: Rosuvastatin 20mg
Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
The Number of Participants Who Experianced Adverse Events and Serious Adverse Events
Time frame: 96 weeks
Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)
Time frame: 96 weeks
Safety and Tolerability in Terms of Growth, Height
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation
Time frame: 96 weeks
Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)
Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.
Time frame: 96 weeks
Safety and Tolerability in Terms of Growth, Weight
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal ECG, Abnormalities
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Physical Exams, Skin
Time frame: 96 weeks
Safety and Tolerability in Terms of Abnormal Vital Signs
Time frame: 96 weeks
Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
Time frame: Up to 22 months
Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg
Time frame: Up to 22 months
The nine (9) patients recruited were all participants in the D3561C00004 HYDRA study (NCT02226198) four came from Sequence A and five from Sequence B
| Milestone | Overall |
|---|---|
| Started | 9 |
| Completed | 4 |
| Not completed | 5 |
| participants | Full Analysis Set |
|---|---|
| The Number of Participants Who Experianced Adverse Events and Serious Adverse Events | 5 |
| participants | Full Analysis Set |
|---|---|
| Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events | 0 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 1 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| cm | Sequence A | Sequence B |
|---|---|---|
| Baseline | 142.5 ± 23.57 | 136.8 ± 15.02 |
| Week 6 | 143.5 ± 23.57 | 136.8 ± 15.32 |
| Week 12 | 144.0 ± 23.90 | 137.6 ± 14.94 |
| Week 18 | 145.3 ± 23.56 | 138.0 ± 14.83 |
| Week 24 | 145.8 ± 24.02 | 139.2 ± 15.74 |
| Week 36 | 147.0 ± 24.15 | 140.6 ± 15.61 |
| Week 48 | 148.8 ± 24.25 | 142.2 ± 15.21 |
| Week 60 | 158.0 ± 19.47 | 144.0 ± 16.37 |
| Week 72 | 159.0 ± 20.22 | 145.0 ± 15.12 |
| Week 84 | 159.7 ± 20.43 | 148.3 ± 17.27 |
| Week 96 | 165.0 ± 25.46 | 138.0 ± 12.73 |
| participants | Full Analysis Set |
|---|---|
| Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation | 0 |
Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.
| standard deviations | Sequence A | Sequence B |
|---|---|---|
| Baseline | -0.43 ± 2.025 | -1.05 ± 1.787 |
| Week 6 | -0.48 ± 1.911 | -1.05 ± 1.871 |
| Week 12 | -0.41 ± 1.975 | -1.19 ± 1.709 |
| Week 18 | -0.43 ± 1.610 | -1.14 ± 1.705 |
| Week 24 | -0.60 ± 1.730 | -0.96 ± 1.670 |
| Week 36 | -0.43 ± 1.836 | -0.76 ± 1.727 |
| Week 48 | -0.16 ± 1.781 | -0.72 ± 1.729 |
| Week 60 | 0.05 ± 1.757 | -1.04 ± 1.604 |
| Week 72 | 0.00 ± 1.635 | -0.87 ± 1.604 |
| Week 84 | 0.08 ± 1.734 | -0.33 ± 1.627 |
| Week 96 | 1.18 ± 0.436 | -0.51 ± 0.886 |
| kg | Sequence A | Sequence B |
|---|---|---|
| Baseline | 36.25 ± 14.719 | 37.42 ± 16.089 |
| Week 6 | 37.20 ± 16.230 | 38.02 ± 16.700 |
| Week 12 | 37.93 ± 17.110 | 38.16 ± 17.501 |
| Week 18 | 38.85 ± 17.633 | 38.40 ± 16.688 |
| Week 24 | 39.15 ± 17.521 | 39.00 ± 16.704 |
| Week 36 | 39.98 ± 18.293 | 39.88 ± 15.015 |
| Week 48 | 41.00 ± 17.579 | 41.16 ± 16.045 |
| Week 60 | 48.47 ± 16.933 | 41.80 ± 15.656 |
| Week 72 | 48.43 ± 16.393 | 42.10 ± 17.047 |
| Week 84 | 50.17 ± 16.737 | 45.28 ± 19.143 |
| Week 96 | 57.35 ± 16.476 | 33.55 ± 2.192 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 1 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 1 ± 15.32 |
| Week 12 | 1 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 1 ± 24.02 | 1 ± 15.74 |
| Week 36 | 1 ± 24.15 | 2 ± 15.61 |
| Week 48 | 1 ± 24.25 | 1 ± 15.21 |
| Week 60 | 1 ± 19.47 | 3 ± 16.37 |
| Week 72 | 2 ± 20.22 | 1 ± 15.12 |
| Week 84 | 1 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 2 ± 23.57 | 3 ± 15.02 |
| Week 6 | 0 ± 23.57 | 2 ± 15.32 |
| Week 12 | 2 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 2 ± 14.83 |
| Week 24 | 2 ± 24.02 | 3 ± 15.74 |
| Week 36 | 1 ± 24.15 | 3 ± 15.61 |
| Week 48 | 1 ± 24.25 | 4 ± 15.21 |
| Week 60 | 1 ± 19.47 | 4 ± 16.37 |
| Week 72 | 2 ± 20.22 | 3 ± 15.12 |
| Week 84 | 2 ± 20.43 | 3 ± 17.27 |
| Week 96 | 0 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 3 ± 15.02 |
| Week 6 | 1 ± 23.57 | 2 ± 15.32 |
| Week 12 | 1 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 2 ± 14.83 |
| Week 24 | 1 ± 24.02 | 2 ± 15.74 |
| Week 36 | 1 ± 24.15 | 2 ± 15.61 |
| Week 48 | 1 ± 24.25 | 3 ± 15.21 |
| Week 60 | 0 ± 19.47 | 3 ± 16.37 |
| Week 72 | 0 ± 20.22 | 3 ± 15.12 |
| Week 84 | 0 ± 20.43 | 3 ± 17.27 |
| Week 96 | 2 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 2 ± 15.02 |
| Week 6 | 1 ± 23.57 | 2 ± 15.32 |
| Week 12 | 1 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 2 ± 14.83 |
| Week 24 | 1 ± 24.02 | 2 ± 15.74 |
| Week 36 | 1 ± 24.15 | 2 ± 15.61 |
| Week 48 | 1 ± 24.25 | 2 ± 15.21 |
| Week 60 | 0 ± 19.47 | 2 ± 16.37 |
| Week 72 | 0 ± 20.22 | 3 ± 15.12 |
| Week 84 | 0 ± 20.43 | 3 ± 17.27 |
| Week 96 | 2 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 1 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 1 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 1 ± 24.02 | 2 ± 15.74 |
| Week 36 | 0 ± 24.15 | 2 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 2 ± 15.12 |
| Week 84 | 0 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 2 ± 23.57 | 2 ± 15.02 |
| Week 6 | 2 ± 23.57 | 3 ± 15.32 |
| Week 12 | 1 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 3 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 1 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 2 ± 15.21 |
| Week 60 | 0 ± 19.47 | 2 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 2 ± 23.57 | 3 ± 15.02 |
| Week 6 | 2 ± 23.57 | 3 ± 15.32 |
| Week 12 | 1 ± 23.90 | 3 ± 14.94 |
| Week 18 | 1 ± 23.56 | 3 ± 14.83 |
| Week 24 | 0 ± 24.02 | 2 ± 15.74 |
| Week 36 | 1 ± 24.15 | 3 ± 15.61 |
| Week 48 | 1 ± 24.25 | 3 ± 15.21 |
| Week 60 | 0 ± 19.47 | 3 ± 16.37 |
| Week 72 | 0 ± 20.22 | 3 ± 15.12 |
| Week 84 | 0 ± 20.43 | 3 ± 17.27 |
| Week 96 | 0 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 1 ± 15.02 |
| Week 6 | 0 ± 23.57 | 1 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 1 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| % change from baseline LDL-C | Full Analysis Set |
|---|---|
| Visit 1 | -21.0 (-32.1 to -8.0) |
| Visit 2 | -18.6 (-28.4 to -7.4) |
| Visit 3 | -14.7 (-25.2 to -2.8) |
| Visit 4 | -12.1 (-23.8 to 1.4) |
| Visit 5 | -21.3 (-33.7 to -6.6) |
| Visit 6 | -20.5 (-33.6 to -4.8) |
| Visit 7 | -12.4 (-28.2 to 7.0) |
| % change from baseline HDL-C | Full Analysis Set |
|---|---|
| Visit 1 | 12.3 (1.3 to 24.5) |
| Visit 2 | 19.0 (6.2 to 33.4) |
| Visit 3 | 5.2 (-8.4 to 20.8) |
| Visit 4 | 4.4 (-10.8 to 22.2) |
| Visit 5 | 4.4 (-12.7 to 24.9) |
| Visit 6 | 9.4 (-9.4 to 32.1) |
| Visit 7 | 3.8 (-13.1 to 23.9) |
| % change from baseline TC | Full Analysis Set |
|---|---|
| Visit 1 | -19.4 (-29.7 to -7.6) |
| Visit 2 | -16.8 (-25.7 to -6.8) |
| Visit 3 | -14.0 (-23.6 to -3.3) |
| Visit 4 | -11.8 (-22.3 to 0.1) |
| Visit 5 | -19.9 (-31.1 to -6.9) |
| Visit 6 | -18.3 (-30.2 to -4.3) |
| Visit 7 | -11.9 (-26.3 to 5.2) |
| % change from baseline TG | Full Analysis Set |
|---|---|
| Visit 1 | -17.3 (-31.9 to 0.5) |
| Visit 2 | -17.4 (-34.2 to 3.8) |
| Visit 3 | -16.2 (-36.1 to 10.1) |
| Visit 4 | -22.0 (-42.8 to 6.5) |
| Visit 5 | -23.3 (-45.0 to 7.1) |
| Visit 6 | -21.7 (-43.4 to 8.4) |
| Visit 7 | -28.5 (-47.0 to -3.6) |
| % change from baseline Non-HDL-C | Full Analysis Set |
|---|---|
| Visit 1 | -21.7 (-32.7 to -9.0) |
| Visit 2 | -19.2 (-28.8 to -8.3) |
| Visit 3 | -15.7 (-25.7 to -4.3) |
| Visit 4 | -13.3 (-24.3 to -0.7) |
| Visit 5 | -22.1 (-33.8 to -8.4) |
| Visit 6 | -21.0 (-33.2 to -6.5) |
| Visit 7 | -13.2 (-28.1 to 4.8) |
| % change from baseline LDL-C/HDL-C | Full Analysis Set |
|---|---|
| Visit 1 | -39.4 (-51.6 to -24.1) |
| Visit 2 | -41.2 (-52.8 to -26.9) |
| Visit 3 | -36.1 (-48.8 to -20.2) |
| Visit 4 | -35.0 (-49.5 to -16.4) |
| Visit 5 | -48.6 (-61.3 to -31.7) |
| Visit 6 | -42.2 (-57.2 to -21.9) |
| Visit 7 | -27.8 (-47.4 to -0.9) |
| % change from baseline TC/HDL-C | Full Analysis Set |
|---|---|
| Visit 1 | -30.6 (-38.3 to -21.9) |
| Visit 2 | -29.4 (-38.5 to -18.9) |
| Visit 3 | -20.5 (-32.0 to -7.0) |
| Visit 4 | -16.6 (-30.7 to 0.4) |
| Visit 5 | -24.1 (-38.6 to -6.2) |
| Visit 6 | -29.2 (-43.2 to -11.7) |
| Visit 7 | -15.6 (-33.7 to 7.5) |
| % change from baseline Non-HDL-C/HDL-C | Full Analysis Set |
|---|---|
| Visit 1 | -32.9 (-41.2 to -23.3) |
| Visit 2 | -31.5 (-41.2 to -20.3) |
| Visit 3 | -22.3 (-34.3 to -8.1) |
| Visit 4 | -18.1 (-32.8 to -0.3) |
| Visit 5 | -26.3 (-41.3 to -7.4) |
| Visit 6 | -31.8 (-46.0 to -13.9) |
| Visit 7 | -17.6 (-36.2 to 6.5) |
| % change from baseline ApoB | Full Analysis Set |
|---|---|
| Visit 1 | -20.5 (-29.8 to -9.9) |
| Visit 2 | -18.7 (-26.7 to -9.8) |
| Visit 3 | -15.2 (-23.9 to -5.6) |
| Visit 4 | -10.5 (-20.4 to 0.5) |
| Visit 5 | -17.2 (-27.9 to -4.9) |
| Visit 6 | -19.2 (-30.2 to -6.5) |
| Visit 7 | -9.5 (-23.5 to 7.2) |
| % change from baseline ApoA-1 | Full Analysis Set |
|---|---|
| Visit 1 | 8.0 (0.0 to 16.6) |
| Visit 2 | 7.0 (-2.3 to 17.1) |
| Visit 3 | 5.3 (-4.9 to 16.7) |
| Visit 4 | 6.5 (-5.3 to 19.7) |
| Visit 5 | 1.0 (-11.5 to 15.3) |
| Visit 6 | 10.7 (-2.6 to 25.7) |
| Visit 7 | 1.6 (-12.9 to 18.4) |
| % change from baseline ApoB/ApoA-1 | Full Analysis Set |
|---|---|
| Visit 1 | -23.3 (-34.3 to -10.5) |
| Visit 2 | -22.1 (-32.7 to -9.8) |
| Visit 3 | -18.9 (-31.2 to -4.4) |
| Visit 4 | -15.7 (-30.2 to 1.7) |
| Visit 5 | -17.0 (-33.1 to 2.8) |
| Visit 6 | -26.0 (-41.1 to -7.0) |
| Visit 7 | -14.7 (-33.7 to 9.7) |
| ng/mL | Full Analysis Set |
|---|---|
| Day 292 | 9.00 |
| Day 376 | 7.14 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 0 ± 15.02 |
| Week 6 | 1 ± 23.57 | 0 ± 15.32 |
| Week 12 | 1 ± 23.90 | 0 ± 14.94 |
| Week 18 | 1 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 1 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 1 ± 15.02 |
| Week 6 | 0 ± 23.57 | 1 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 1 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 1 ± 24.02 | 0 ± 15.74 |
| Week 36 | 1 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 1 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 1 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 1 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 2 ± 23.57 | 0 ± 15.02 |
| Week 6 | 1 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 3 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 0 ± 15.02 |
| Week 6 | 1 ± 23.57 | 1 ± 15.32 |
| Week 12 | 1 ± 23.90 | 0 ± 14.94 |
| Week 18 | 1 ± 23.56 | 1 ± 14.83 |
| Week 24 | 1 ± 24.02 | 1 ± 15.74 |
| Week 36 | 1 ± 24.15 | 1 ± 15.61 |
| Week 48 | 1 ± 24.25 | 1 ± 15.21 |
| Week 60 | 1 ± 19.47 | 1 ± 16.37 |
| Week 72 | 1 ± 20.22 | 1 ± 15.12 |
| Week 84 | 1 ± 20.43 | 1 ± 17.27 |
| Week 96 | 1 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 1 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 1 ± 15.02 |
| Week 6 | 2 ± 23.57 | 1 ± 15.32 |
| Week 12 | 1 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 1 ± 14.83 |
| Week 24 | 1 ± 24.02 | 1 ± 15.74 |
| Week 36 | 1 ± 24.15 | 1 ± 15.61 |
| Week 48 | 1 ± 24.25 | 1 ± 15.21 |
| Week 60 | 1 ± 19.47 | 1 ± 16.37 |
| Week 72 | 2 ± 20.22 | 1 ± 15.12 |
| Week 84 | 1 ± 20.43 | 1 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 2 ± 23.57 | 1 ± 15.02 |
| Week 6 | 1 ± 23.57 | 1 ± 15.32 |
| Week 12 | 2 ± 23.90 | 1 ± 14.94 |
| Week 18 | 1 ± 23.56 | 0 ± 14.83 |
| Week 24 | 2 ± 24.02 | 1 ± 15.74 |
| Week 36 | 2 ± 24.15 | 0 ± 15.61 |
| Week 48 | 1 ± 24.25 | 1 ± 15.21 |
| Week 60 | 3 ± 19.47 | 1 ± 16.37 |
| Week 72 | 3 ± 20.22 | 1 ± 15.12 |
| Week 84 | 2 ± 20.43 | 1 ± 17.27 |
| Week 96 | 1 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Final Visit | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 1 ± 23.57 | 2 ± 15.02 |
| Week 6 | 1 ± 23.57 | 2 ± 15.32 |
| Week 12 | 1 ± 23.90 | 2 ± 14.94 |
| Week 18 | 1 ± 23.56 | 2 ± 14.83 |
| Week 24 | 1 ± 24.02 | 2 ± 15.74 |
| Week 36 | 1 ± 24.15 | 2 ± 15.61 |
| Week 48 | 1 ± 24.25 | 2 ± 15.21 |
| Week 60 | 1 ± 19.47 | 2 ± 16.37 |
| Week 72 | 1 ± 20.22 | 2 ± 15.12 |
| Week 84 | 1 ± 20.43 | 2 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 1 ± 15.02 |
| Week 6 | 0 ± 23.57 | 1 ± 15.32 |
| Week 12 | 0 ± 23.90 | 1 ± 14.94 |
| Week 18 | 0 ± 23.56 | 1 ± 14.83 |
| Week 24 | 0 ± 24.02 | 1 ± 15.74 |
| Week 36 | 0 ± 24.15 | 1 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 1 ± 16.37 |
| Week 72 | 0 ± 20.22 | 1 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 1 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 3 ± 23.57 | 2 ± 15.02 |
| Week 6 | 3 ± 23.57 | 2 ± 15.32 |
| Week 12 | 3 ± 23.90 | 2 ± 14.94 |
| Week 18 | 3 ± 23.56 | 2 ± 14.83 |
| Week 24 | 3 ± 24.02 | 2 ± 15.74 |
| Week 36 | 3 ± 24.15 | 2 ± 15.61 |
| Week 48 | 3 ± 24.25 | 2 ± 15.21 |
| Week 60 | 2 ± 19.47 | 2 ± 16.37 |
| Week 72 | 2 ± 20.22 | 2 ± 15.12 |
| Week 84 | 2 ± 20.43 | 1 ± 17.27 |
| Week 96 | 2 ± 25.46 | 1 ± 12.73 |
| participants | Sequence A | Sequence B |
|---|---|---|
| Baseline | 0 ± 23.57 | 0 ± 15.02 |
| Week 6 | 0 ± 23.57 | 0 ± 15.32 |
| Week 12 | 0 ± 23.90 | 0 ± 14.94 |
| Week 18 | 0 ± 23.56 | 0 ± 14.83 |
| Week 24 | 0 ± 24.02 | 0 ± 15.74 |
| Week 36 | 0 ± 24.15 | 0 ± 15.61 |
| Week 48 | 0 ± 24.25 | 0 ± 15.21 |
| Week 60 | 0 ± 19.47 | 0 ± 16.37 |
| Week 72 | 0 ± 20.22 | 0 ± 15.12 |
| Week 84 | 0 ± 20.43 | 0 ± 17.27 |
| Week 96 | 0 ± 25.46 | 0 ± 12.73 |
Collected over 72 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | — | 0/9 (0%) | 5/9 (55.6%) |
| Event | Overall |
|---|---|
| NasopharyngitisInfections and infestations | 2/9 |
| Otitis externaInfections and infestations | 1/9 |
| Upper respiratory tract infectionInfections and infestations | 1/9 |
| DysuriaRenal and urinary disorders | 1/9 |
| ProteinuriaRenal and urinary disorders | 1/9 |
| Chest discomfortGeneral disorders | 1/9 |
| Ligament sprainInjury, poisoning and procedural complications | 1/9 |
| Attention deficit/hyperactivity disorderPsychiatric disorders | 1/9 |
| DysmenorrhoeaReproductive system and breast disorders | 1/9 |
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 10.6 ± 2.83 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 4 |
| Male | 5 |
Ran from Jun 2015 to primary completion in Nov 2016, 17 months.
Results were first posted in Feb 2018, 1 year 3 months after primary completion.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin
Homozygous Familial Hypercholesterolemia →